Arvinas updates Phase 3 vepdegestrant combo trials; VERITAC-2 topline data expected Q1 2025

ARVINAS, INC.

Topline data for VERITAC-2 Phase 3 monotherapy trial of vepdegestrant expected in Q1 2025.
First-line Phase 3 combo with Pfizer's atirmociclib planned for 2025; VERITAC-3 (palbociclib combo) discontinued.
Phase 1 trial of ARV-102 (LRRK2 degrader) in Parkinson's disease initiated; data at AD/PD conference April 2025.
Alex Santini appointed interim CCO effective Jan 17, 2025; John Northcott leaving for personal reasons.
IND filing for KRAS G12D degrader and initial data from ARV-393 (BCL6 degrader) expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.